In its response to lawmakers, IU emphasized the role of public health in health care costs and called on lawmakers to spend more on public health. It pointed to a recent study that ranked Indiana 47th among states in per-person public health funding.
In addition to changing the dashboard’s format, the Indiana Department of Health said it would shrink the its publication schedule from five days a week to three days.
When the end of the COVID-19 pandemic comes, it could create major disruptions for a cumbersome U.S. health care system made more generous, flexible and up-to-date technologically through a raft of temporary emergency measures.
The FDA has also emphasized the need for “regulatory flexibility” when reviewing drugs for fatal diseases like ALS. The panel’s close vote could tip the agency toward an approval, given the lack of options currently available.
On Wednesday, a panel of FDA advisers will take a non-binding vote on whether the drug warrants approval. The meeting is being closely watched as an indicator of the FDA’s approach to experimental drugs with imperfect data and its ability to withstand outside pressure.
The effort to stamp out the chemicals comes in response to an investigation by Consumer Reports that found toxic chemicals in a majority of the food wrappers and packaging from chain restaurants and grocery stores that were tested.
In making their case, executives cited the “persistent and steady decline” of hospitalizations and death rates related to the coronavirus.
Hospitalizations have plummeted 90% since hitting a pandemic high of 3,519 on Jan. 13. COVID patients occupy only 2.9% of Indiana’s intensive care unit beds.
Scores of projects across the United States are being funded with federal coronavirus relief money despite having little to do with combating the pandemic, a review by The Associated Press has found.
One reason the variant has gained ground, scientists say, is that it’s about 30% more contagious than the original omicron.
With an urgent funding request stuck in Congress, a federal agency says it can no longer cover COVID test and treatment bills for uninsured people and will stop taking claims at midnight Tuesday.
The goal is to get patients started on either Pfizer’s Paxlovid tablets or Merck’s molnupiravir capsules within five days of symptoms appearing. But the tight deadline has highlighted several challenges.
Although some fully vaccinated and boosted people came down with mild infections during the omicron surge, the study showed that the vaccines—and especially the booster shot—protected most people from the virus’s worst effects.
U.S. cigarette smoking dropped to a new all-time low in 2020, according to survey data released Thursday by the Centers for Disease Control and Prevention.
The company said its request for approval for all adults was made “to provide flexibility” to the Centers for Disease Control and Prevention and medical providers to determine the “appropriate use” of a second booster dose of the vaccine.
It’s clear that in those who already have diabetes, COVID-19 can worsen the condition and lead to severe complications. But there are other possible links.
Additionally, the pharmaceutical giant said in a statement that it had “suspended all investments, promotional activities, and new clinical trials in Russia.”
The decision from the FDA could come relatively quickly, especially if officials conclude the data is straightforward and does not have to be reviewed by a panel of outside vaccine experts.
The mask mandate was scheduled to expire March 18, but the Transportation Security Administration said Thursday that it will extend the requirement through April 18.
A congressional panel on Wednesday debated whether to end the nation’s “spring forward” and “fall back” daylight saving policy, citing the health effects of shifting the clock twice per year. Most agreed it was about time.
